• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 202

Featured

Most popular
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Reunion Sues Mindset, Claims it Copied RE104

PT406 – Bicycle Day, Unveiling Entheon, and The Mystical Experience Through...

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

BetterLife Files Amended and Restated Offering Document for Offering of Units

Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia

MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT

Looking Ahead to a Psychedelic 2023

PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use...

Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference...

1...201202203...215Page 202 of 215

EDITOR PICKS

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©